HCC tissues; matched normal samples; HCC tumor tissues; adjacent normal tissues; peripheral blood
MHCC97; Hep3B; Huh-7; THLE-2; THP-1; HEK-293 T; PBMCs; CIK cells
cell line-derived xenograft
proliferation (promotes); invasion (promotes); stemness (promotes); apoptosis (inhibits); immune regulation (promotes); macrophage polarization (promotes); ceRNA regulation (other); m6A modification (other); other pathway/process (promotes)
RNase R Treatment; RT-qPCR; Microarray; MTT; EdU Staining; Annexin V/PI Flow Cytometry; Flow Cytometry(Non-apoptosis/cycle); Transwell Assay; ELISA; Western Blot; IHC (Immunohistochemistry); Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; MeRIP / MeRIP-seq; Transfection; In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis; Nuclear-Cytoplasmic Fractionation
High circ_0027791 expression is associated with lower overall survival and may provide a new prognostic and therapeutic marker for HCC.
circ_0027791 is upregulated in HCC tissues and cells, and high expression is associated with poorer overall survival. Functionally, it promotes HCC proliferation, invasion, sphere formation, tumor growth, M2 macrophage polarization, and immune evasion. Mechanistically, METTL3-mediated m6A modification stabilizes circ_0027791, which sponges miR-496 to increase PDL1 expression.
0.8611
Circ_0027791 contributes to the growth and immune evasion of hepatocellular carcinoma via the miR-496/programmed cell death ligand 1 axis in an m6A-dependent manner.
combined biological and clinical study